Form 4: Prelude Therapeutics Executive Jane Huang Reports Stock Transactions
SEC Form 4 Filing
Jane Huang, President and CMO of Prelude Therapeutics, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Summary
- On January 4, 2025, Jane Huang, President and CMO of Prelude Therapeutics, reported transactions involving the company's common stock.
- Huang vested 9,375 shares of common stock through the vesting of Restricted Stock Units (RSUs).
- 3,859 shares were withheld by the issuer to satisfy tax obligations related to the RSU vesting at a price of $1.39.
- Following these transactions, Huang directly owns 68,857 shares of Prelude Therapeutics common stock and 46,875 Restricted Stock Units.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock vesting and tax obligations, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.
Stakeholder Impact
- Shareholders gain insight into executive compensation and stock ownership.
- Employees are affected through the vesting of their stock options and RSUs.
Key Dates
| Date | Description |
|---|---|
| May 2, 2022 | RSUs were granted to Jane Huang. |
| April 4, 2023 | 1/4 of the total RSU shares vested. |
| January 4, 2025 | RSU vesting and tax withholding occurred. |
| January 7, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.